Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Fax+1 713-563-0566
Dr. Naing is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2002 - 2005
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1999 - 2002
Hacettepe University FOMClass of 1997
Certifications & Licensure
CA State Medical License 2002 - Present
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2027
GA State Medical License 2023 - 2027
TN State Medical License 2023 - 2027
AL State Medical License 2023 - 2026
LA State Medical License 2023 - 2026
American Board of Internal Medicine Medical Oncology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
Clinical Trials
- Olanzapine in Patients With Advanced Cancer and Weight Loss Start of enrollment: 2006 Oct 01
- Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor Start of enrollment: 2007 Jun 01
- Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies Start of enrollment: 2006 Sep 13
Publications & Presentations
PubMed
- DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix.Young Kwang Chae, Megan Othus, Sandip P Patel, Floortje J Backes, David M O'Malley
Journal for Immunotherapy of Cancer. 2026-02-11 - Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion.Sarina A Piha-Paul, Chieh Tseng, Emily Thompson, R Jason Stafford, Hung Le
The Oncologist. 2026-02-05 - Tumor microenvironment changes after treatment with avelumab and immune-stimulating agent combinations in patients with advanced solid tumors.Nejla Ozirmak Lermi, Mohamed A Gouda, Jibran Ahmed, Xianli Jiang, Younghee Lee
Research Square. 2026-01-19
Journal Articles
- Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational StudyFelipe Samaniego, Boris Blechacz, Ahmed Kaseb, Bruno P Granwehr, Aung Naing, Issam I Raad, Ethan Miller, Harrys A Torres, Nature
- Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse CancersRavi Murthy, Robert S Benjamin, Anthony P Conley, Chitra Hosing, David S Hong, Aung Naing, Clinical Cancer Research
Lectures
- CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072.2019 ASCO Annual Meeting - 6/1/2019
- A multicenter, open label, first-in-human study of an oncolytic viral vector expressing an agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors (F...2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024November 8th, 2024- Invectys and CTMC Announce FDA Clearance of IND Application for Anti-HLA-G CAR-T Cell TherapyDecember 19th, 2022
- MD Anderson Research Highlights for April 13, 2022April 13th, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
